Prevalence of Carbapenem Resistance in Gram Negative Bacilli Isolates and Their Antimicrobial Susceptibility Pattern

Similar documents
In-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria

Detection of Carbapenem Resistant Enterobacteriacae from Clinical Isolates

Differentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test

Screening of Carbapenem Resistant Enterobacteriaceae among Nosocomial Isolates: A Study from South India

Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital

Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae

Incidence of metallo beta lactamase producing Pseudomonas aeruginosa in ICU patients

High Incidence of Multidrug Resistant Pseudomonas aeruginosa Isolated from Infected Burn Wounds in a Tertiary Hospital

ALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella

Metallo beta-lactamases mediated resistance in Pseudomonas aeruginosa from clinical samples in a teaching hospital of North India.

Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011

SSRG International Journal of Medical Science (SSRG-IJMS) volume 2 Issue 4 April 2015

Screening and detection of carbapenemases

Discussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category

NONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN

Detecting CRE. what does one need to do?

BACTERIOLOGICAL PROFILE OF DIABETIC FOOT INFECTIONS

Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH

Laboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator

Infection Control Strategies to Avoid Carbapenam Resistance in Hospitals. Victor Lim International Medical University Malaysia

Comparision of Antibiotic Susceptibility Testing As Per CLSI and Eucast Guidelines for Gram Negative Bacilli

Carbapenems and Enterobacteriaceae

Insert for Kit 98006/98010/ KPC/Metallo-B-Lactamase Confirm Kit KPC+MBL detection Kit KPC/MBL and OXA-48 Confirm Kit REVISION: DBV0034J

Prevalence of ESBL producing enterobacteriaceae in diabetic foot ulcers

Expert rules. for Gram-negatives

Overcoming the PosESBLities of Enterobacteriaceae Resistance

The Occurrence of (MDR/MDS) Pseudomonas aeruginosa among Nosocomial and Community Acquired Infections in and around Coimbatore, India

AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac

Microbiology, 5 Dept. of Community Medicine, *Corresponding Author:

Nature and Science 2017;15(10)

Comparison of Different Phenotypic Tests for the Detection of Metallo-B-Lactamase (MBL) Producing Pseudomonas aeruginosa

MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions

EVALUATION OF METHODS FOR AMPC β-lactamase IN GRAM NEGATIVE CLINICAL ISOLATES FROM TERTIARY CARE HOSPITALS

Nightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017

HOSPITAL EPIDEMOLOGY AND INFECTION CONTROL: STANDARD AND TRANSMISSION-BASED ISOLATION

Sensitivity of Surveillance Testing for Multidrug-Resistant Gram-Negative Bacteria in the

10/4/16. mcr-1. Emerging Resistance Updates. Objectives. National Center for Emerging and Zoonotic Infectious Diseases. Alex Kallen, MD, MPH, FACP

Surveillance of antimicrobial susceptibility of Enterobacteriaceae pathogens isolated from intensive care units and surgical units in Russia

Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.

A Snapshot of Colistin Use in South-East Europe and Particularly in Greece

Urinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014

Annual Surveillance Summary: Klebsiella species Infections in the Military Health System (MHS), 2017

Expert rules in antimicrobial susceptibility testing: State of the art

Carbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School

Journal of Infectious Diseases and

Antibacterial Activity of ZnO Nanoparticles against ESBL and Amp-C Producing Gram Negative Isolates from Superficial Wound Infections

ST11 KPC-2 Klebsiella pneumoniae detected in Taiwan

Sensitive and specific Modified Hodge Test for KPC and metallo-beta-lactamase

In Vitro Susceptibility Pattern of Cephalosporin- Resistant Gram-Negative Bacteria

2612 Page. *Yusuf, I 1., Rabiu A.T 1., Haruna, M 2. and Abdullahi, S. A 3. Phone:

Adenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes

Academic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE

Update on CLSI and EUCAST

AMPC BETA LACTAMASES AMONG GRAM NEGATIVE CLINICAL ISOLATES FROM A TERTIARY HOSPITAL, SOUTH INDIA. Mohamudha Parveen R., Harish B.N., Parija S.C.

Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED

Public Health Surveillance for Multi Drug Resistant Organisms in Orange County

Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae in Taiwan

What is new in EUCAST South Africa, May, Gunnar Kahlmeter EUCAST Technical Data Coordinator and Webmaster Sweden

EUCAST Frequently Asked Questions. by author. Rafael Cantón Hospital Universitario Ramón y Cajal, Madrid, Spain EUCAST Clinical Data Coordinator

Carbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.

The CLSI Approach to Setting Breakpoints

Aerobic bacterial Profile of Diabetic Foot Ulcers and their Antibiotic Sensitivity Pattern

Methodological and interpretative problems in antimicrobial susceptiblity tests of P. aeruginosa

β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication

Antibiotic Treatment of GNR MDR Infections. Stan Deresinski

Determining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing

GUIDE TO INFECTION CONTROL IN THE HOSPITAL. Carbapenem-resistant Enterobacteriaceae

Detecting carbapenemases in Enterobacteriaceae

Global Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE)

Standardisation of testing for Carbapenemase Producing Organisms (CPO) in Scotland

ORIGINAL ARTICLE SUSCEPTIBILITY PATTERNS IN GRAM NEGATIVE URINARY ISOLATES TO CIPROFLOXACIN, CO-TRIMOXAZOLE AND NITROFURANTOIN

Research Article Antimicrobial Susceptibility Patterns of Pseudomonas aeruginosa from Diabetes Patients with Foot Ulcers

Revised AAC Version 2» New-Data Letter to the Editor ACCEPTED. Plasmid-Mediated Carbapenem-Hydrolyzing β-lactamase KPC-2 in

Sep Oct Nov Dec Total

Recommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals

National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats

CHAPTER 8 ANTIBACTERIAL ACTIVITY OF THE CRUDE ETHANOLIC EXTRACT AND THE ISOLATED COMPOUNDS FROM THE STEM OF COSTUS IGNEUS

Translocation Studies Mid-Term Review (MTR) Meeting Marseille, France

International Journal of Current Microbiology and Applied Sciences ISSN: Volume 7 Number 01 (2018) Journal homepage:

Urinary Tract Infection and Pattern of Antibiotic Sensitivity in Hospitalized Patients with Diabetes Mellitus in Myanmar

Reporting blood culture results to clinicians: MIC, resistance mechanisms, both?

The role of an AMR reference laboratory

Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2016

Ceftazidime-Avibactam and Aztreonam an interesting strategy to Overcome β- Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae

/01/$ DOI: /JCM Copyright 2001, American Society for Microbiology. All Rights Reserved.

Emergence of non-kpc carbapenemases: NDM and more

Received 31 January 2011/Returned for modification 2 March 2011/Accepted 15 March 2011

Regional Emergence of VIM producing carbapenem resistant Pseudomonas aeruginosa (VIM CRPA)

Report on susceptibility of Salmonella serotypes in Belgium Vicky Jasson

Guess or get it right?

Phenotypic detection of ESBLs and carbapenemases

Controversial Issues in Susceptibility Testing: Point/Counterpoint. April N. Abbott, PhD D(ABMM) Romney M. Humphries, PhD D(ABMM)

Use of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles

ORIGINAL ARTICLE. Julie Creighton and Clare Tibbs. Canterbury Health Laboratories, Christchurch

Educational Workshops 2016

Antibiotic Usage Related to Microorganisms Pattern and MIC

Development of a phenotypic method for fecal carriage detection of OXA-48-producing

Noelisa Montero, MPH. Epidemiologist Consultant. October 19, 2017 Connecticut Department of Public Health Healthcare Associated Infections Program

Enterobacteriaceae with acquired carbapenemases, 2016

Annual Surveillance Summary: Pseudomonas aeruginosa Infections in the Military Health System (MHS), 2017

Transcription:

Original Research Article Prevalence of Carbapenem Resistance in Gram Negative Bacilli Isolates and Their Antimicrobial Susceptibility Pattern Monika Saini 1, Aditya Mishra 2*, Sweta Gupta 3 1 M.Sc Medical Microbiology, 3 Professor & Head, Department of Microbiology, Mahatma Gandhi Medical College & Hospital, Jaipur, Rajasthan, INDIA. 2* Ph.D Scholar SMS Medical College, Jaipur, Rajasthan, INDIA. ABSTRACT Aim: The objective of study is to evaluate the prevalence of carbapenem resistance in gram negative bacilli isolates and their antimicrobial susceptibility pattern. Method: All the samples received in the Microbiology laboratory from the various departments were cultured on Blood and MacConkey s agar and blood was on Brain heart infusion broth. Antibiogram was done by Modified Kirby Bauer disk diffusion method. Detection of Metallo beta lactamase (MBL) cases were done by double disc synergy test and confirmed by E-test of Meropenem. Result: Total 500 samples were tested in this study. Out of 500, 350 gram negative bacilli were reported. Out of 350, 100 (29%) were carbapenem resistant. 97% Carbapenem resistant organism were isolated from IPD patients. Maximum 65% Carbapenem resistant gram negative bacilli (CRGNB) isolated from respiratory tract infection cases. Total 44% Acinetobacter, 25% E.coli, 17%, Klebsiella, 12% Pseudomonas and 2 % others CRGNB were isolated. Out of 100 CRGNB cases, 83 were found MBL. Acinetobacter were the most common MBL producer. Acinetobacter were 100% MBL while Klebsiella were 76.47%, Pseudomonas 66.66% and E.coli 64%. All CRGNB were sensitive to Colistin. Conclusion: Drug resistant microorganisms are increasing rapidly and becoming major problem for society. To control the INTRODUCTION Antibiotic resistance is now becoming a global threat. The burden is more in developing countries where infectious diseases are building up. In the developing countries, there is rampant use of antibiotics mainly because, due to limited resources, most clinicians choose symptomatic treatment that s why very few microbiological samples are taken for culture and antibiotic sensitivity testing 1,2. In addition there is an extensive over the counter treatment with widespread self-medication and incomplete course of antibiotics. These are well known factors that facilitate development of antibiotic resistance. Carbapenem are a group of β-lactam antimicrobial agents with an exceptionally broad spectrum of activity 1. They are used as a last resort drug against many MDR microorganisms such as Extended spectrum beta-lactamase (ESBL), Metallo beta lactamase (MBL) and AmpC enzyme producing gram negative bacilli 3. The emergence and transmission of carbapenem resistant bacteria in recent time represents a serious threat to public health. Resistance has been observed in the family of enterobacteriaceae, as well as in members of the Pseudomonas and Acinetobacter genera. These organisms are associated with MBL producing microorganisms in a hospital/health care setup, strategies such as strict infection control measures, antibiotics resistance surveillance programs & restrict to clinicians, prescribe last resort drugs only where primary & secondary drugs are resistant and antibiotic cycling must be followed. Colistin could be a drug of choice in CRGNB infections. Keywords: Carbapenem resistant gram negative bacilli (CRGNB), Metallo beta lactamase (MBL). *Correspondence to: Aditya Mishra, Ph.D Scholar, SMS Medical College, Jaipur, Rajasthan, INDIA. Email: aditya.mishrajpr@gmail.com Article History: Received: 02-05-2016, Revised: 07-05-2016, Accepted: 09-05-2016 Website: www.ijmrp.com DOI: 10.21276/ijmrp.2016.2.3.006 Access this article online Quick Response code high mortality rates and have the potential to spread widely 4. Resistance to carbapenems can be brought about by various mechanisms, the most common being the production of carbapenemases, a class of enzymes capable of hydrolyzing Carbapenem and other beta lactam 5. Resistance to Carbapenem can also be due to the poor binding of Carbapenem to penicillinbinding proteins present in the bacteria, the over-expression of multidrug efflux pumps by the bacteria or lack of porins present in the bacterial cell membrane. However, for significant resistance to emerge, it is the thought that a combination of resistance mechanisms is required 6. In 2007, the overall worldwide susceptibility to carbapenems was 98% among the enterobacteriaceae. Presumably this was due to a number of factors, including antibiotic usage, dosing regimens and local hospital practices concerning isolation of patients with MDR microorganisms 7. With the increasing incidence of Carbapenem resistant gram negative bacilli (CRGNB) in hospitals, a rapid and detection is required. Appropriate detection of CRGNB is vital in patient care and infection control in order to institute correct, targeted treatment and to reduce the escalation of 28 P a g e Int J Med Res Prof.2016; 2(3); 28-32. www.ijmrp.com

resistance 5. The objective of study is to evaluate the magnitude of carbapenem resistance in gram negative bacilli isolates. MATERIAL AND METHODS Samples were collected from various wards, Indoor & outdoor patient departments of Mahatma Gandhi medical college & Hospital, Jaipur from October 2014 to March 2015. Clinical samples such as blood, CSF, urine, respiratory secretions, swabs from non-healing ulcers, pus/wound swab & other samples from sterile body fluids were collected by taking aseptic precautions. All the samples except blood were cultured on blood agar, MacConkey s agar & Thioglycolate broth. Blood culture was done on Brain heart infusion broth. A culture plates were incubated overnight at 37ºC. Isolated gram negative organisms were further identified by standard set of biochemical tests 8. Gram Negative bacilli isolates from the various samples; which were having less sensitivity zone size of Imipenem and Meropenem on modified Kirby Bauer disk diffusion method were suspected for carbapenem resistance and tested for MBL detection by Meropenem E-test. 1. Antibiotic susceptibility testing (Anti-biogram): Antimicrobial sensitivity testing was performed on Mueller Hinton agar (Hi-Media, Mumbai) plates by disk diffusion method according to CLSI guidelines 9. The diameter of the zones of inhibition on MHA was interpreted as sensitive, intermediate and resistant. Escherichia coli ATCC 25922 (β-lactamase negative) Pseudomonas aeruginosa ATCC 27853 (β- lactamase negative) and Klebsiella pneumoniae ATCC 700603 (ESBL positive) strains were used as control organisms. Organism with intermediate levels of resistance to the antibiotics Meropenem & Imipenem were included in percentage of resistant organisms for final analysis.by Imipenem & EDTA combined disc Imipenem test. 2. Double disc synergy test (DDST) using Imipenem and Imipenem plus EDTA: Test organism was inoculated on to plates with Mueller Hinton agar as recommended by the CLSI 9. An Imipenem (10 µg) disc was placed 20mm centre to centre from a disc containing 10µg Imipenem plus 0.5 M EDTA. After overnight incubation, a zone diameter difference of 7 mm between Imipenem disc & Imipenem plus EDTA disc were interpreted as Metallo-β-Lactamse positive 9. [Img. 1] 3. MBL E-Test: For MIC detection of Meropenem, the E-test strip method is used. The E-test MBL strip (Hi-Media) containing a double sided even dilution range of Meropenem (MRP 4 to 256 µg /ml) gradient at one end & Meropenem + EDTA (1 to 64 µg/ml) in incubation with a fixed concentration of EDTA at these other end. 100-mmdiameter Mueller-Hinton Agar plates are inoculated with swabs saturated with suspensions of the study isolates equivalent to a 0.5 McFarland standard. The results were read after 24 hrs of the incubation. The ratio of the MIC of Meropenem/ (Meropenem+EDTA) > 8 dilution indicate MBL production 10. [Img. 2] RESULTS Total 500 non-repetitive variable samples from various wards were collected and processed in the Department of Microbiology, Mahatma Gandhi Medical College and Hospital, Jaipur. Out of 500, 350 gram negative bacilli were isolated. These 350 GNB were further processed for the detection of carbapenemase resistance & other antibiotic sensitivity test by disk diffusion method on Muller Hinton Agar as per CLSI guideline. Out of 350, 100(29%) samples were found CRGNB (carbapenem Resistant Gram Negative Bacilli) rest 71% was sensitive to carbapenems. In 100 CRGNB samples 61% were obtained from males and 39% from females. Maximum 19 cases were in between the age of 41-50 years & mean of the age was 44.9 ±20.53. 97% CRGNB were isolated from various wards & ICUs while only 3 % were found in OPD [Fig 1, Fig 2]. Out of 100 CRGNB cases, 65% were reported from respiratory tract infections while18% from wound infections, 13% of Urinary tract infections and 2% each from meningitis & bacteremia were found. [Fig 3] Various antibiotics included in the study were sourced from commercial batches belonging to β-lactam, aminoglycoside, quinolone, and tetracycline classes as per the CLSI guideline. Carbapenem resistant organisms were not only resistant to carbapenem group but also resist to most of antibiotics. CRGNB isolated from UTI were sensitive to fosfomycin & nitrofurantion. Colistin is only drug which showed 100% sensitivity in all CRGNB isolates. [Table 1] Total 83 cases were MBL reported out of 100 CRGNB by Meropenem with & without EDTA Ezy MIC Strips. Maximum resistance was found in member of Acinetobacter. [Fig. 4] DISCUSSION The overall carbapenem resistance in the present study was 29%. The carbapenem resistance rate among GNB varies widely in the literature. Taneja et al. reported it was 36.4%, Gladstone et al. were found 12.2% while Gupta et al mentioned it 17.32% and Datta et al documented it as 7.87% 3,11. The incidence varies from as low as 1.8% to over 30% in India 12,13. In our study among 237 Enterobacteriaceae, 18.56% (44) were resistant to carbapenems. This resistance rate was compare with several studies done in India. Many authors have used one or more carbapenems as indicator drug for testing resistance to carbapenems by disc diffusion or MIC method. Resistance to carbapenems ranged from 2% to 22% in Indian studies. Gupta et al reported less carbapenem resistance rate 3.61% 12 while Gladstone et al found 12.2%, wattal et al 13-51%, Datta et al 17-22% and Dardi kaur et al reported 8.33% 5,14,15. In the present study, out of 113 NFGNB 56 (49.55%) were resistant to carbapenems. Out of 56 CR-NFGNB 44 was Acinetobacter &12 were P. aeruginosa. Pseudomonas carbapenem resistant was 10.61% (12/113) in the present study. In Indian studies, carbapenem resistance in P. aeruginosa has been reported from centres in Pondicherry, Vellore, Bangalore, Chandigarh, Mumbai, New Delhi and Varanasi with the rates of resistance between 10.9% and 69% 16,17. In 83 Acinetobacter isolates out of 113 NFGNB 38.93% (44/113) were carbapenem resistant. Although molecular techniques are regarded as the most appropriate method for the detection of carbapenem resistance, it becomes impractical in a routine diagnostic laboratory setup up due to cost factors, availability of molecular set up. CRGNB infected patients serve as reservoirs for spreading infection and contaminating the environment. That s why, identified CRGNB colonized patients must be contact isolated. 29 P a g e Int J Med Res Prof.2016; 2(3); 28-32. www.ijmrp.com

Img 1: Detection of MBL in E.coli by DDST. ENT 4% Pediatric 5% Pvt & TPA 8% Medicine 9% Casualty, Ortho & CTVSR (each)2% Surgery 8% OPD 3% ICU 55% Img 2: Detection of MBL Pseudomonas by E-Test Pseudomonas 12% Klebsiella 17% Proteus 1% E.coli 25% Citrobacter 1% Acinetobacter 44% Fig 1: Distribution of the CRGNB isolates from various wards Fig 2: Distribution of CRGNB isolates. Distribution of CRGNB isolates from various samples. Escherichia coli Klebsiella Pesudomonas Acinetobacter 41 11 11 7 6 7 2 5 2 2 0 0 0 1 0 1 0 1 1 0 50 40 RTI Wound Infection UTI Meningitis Bacteremia Fig 3: CRGNB isolates from various samples. Meropenem MIC level of Gram Negative Bacilli 30 20 10 0 4 6 8 16 24 32 48 64 128 >256 E.coli Klebsiella Proteus Citrobacter Pseudomonas Acinetobacter Fig 4: MIC level of Meropenem in Gram Negative bacilli 30 P a g e Int J Med Res Prof.2016; 2(3); 28-32. www.ijmrp.com

RTI (n=7) Antibiotic disc Wound Infection (n=7) UTI (n=11) RTI (n=11) Wound Infection (n=2) UTI (n=2) Meningitis (n=1) Bacteremia (n=1) Wound Infection (n=1) Wound Infection (n=1) RTI (n=6) Wound Infection (n=5) Bacteremia (n=1) RTI (n=41) Wound Infection (n=2) Meningitis (n=1) Sensitivity % Monika Saini et al. Prevalence of CRGNB Isolates and Their Antimicrobial Susceptibility Pattern E.coli n= 25 Table 1: Antibiotic sensitivity pattern of CRGNB clinical isolates. Klebsiella Proteus Citrobacter Pseudomonas n= 17 n=1 n=1 n=12 Acinetobacter n=44 Cl 7 7 11 11 2 2 1 1 1 1 6 5 1 41 2 1 100% Pi 2 0 2 2 0 1 0 0 1 0 1 0 1 5 0 0 15% PiT 2 0 2 2 0 1 0 0 1 1 3 2 1 5 2 1 23% OF 2 3 2 5 0 2 1 0 0 0 0 0 0 0 0 0 15% CAZ 1 0 1 2 0 1 1 0 0 0 0 0 0 0 0 0 6% MRP 2 0 2 1 1 1 1 1 0 0 1 1 1 1 0 0 13% IMP 4 2 3 2 1 1 1 1 0 0 1 0 0 1 0 0 17% ETP 1 1 3 0 0 1 1 1 0 1 - - - - - - 16.6% DO 2 2 5 1 1 1 - - - - 0 0 0 1 1 1 15% GEN 0 1 1 0 0 0 0 0-1 0 0 0 1 0 0 04% COT 1 1 0 0 0 1 1 0 1 1 0 0 0 0 0 0 06% AT 1 0 0 0 0 0 0 0-1 - - - - - - 4.65% A/S 3 0 0 2 0 0 0 0 1 1 1 0 0 22 2 1 33% CPM 1 0 0 4 0 0 1 1 0 0 1 0 0 0 0 0 8% TGC 6 5 10 10 2 2 1 1-1 - - - 16 2 1 65.5% LE 1 0-3 0-0 0 1 1 - - - 8 1 1 21.3% AK 1 1 7 3 0 2 0 0 1 1 2 0 0 0 0 0 18% PB - - - - - - - - - - 6 5 1 0 0 0 25.3% CB - - - - - - - - - - 4 1 1 19 2 1 50% TOB - - - - - - - - - - 2 0 0 3 1 0 10.7% FO - - 11 - - 2 - - 1 - - - - - - - 100% NIT - - 7 - - 0 - - - - - - - - - - 53.84% Cl Colistin, Pi Piperacillin, PiT- Piperacillin-Tazobactum, OF- Ofloxacin, CAZ- Ceftazidime, MRP- Meropenem, IMP- Imipenem, ETP- Ertapenem, DO-Doxycycline, GEN- Gentamycin, COT- Cotrimoxazole, AT- Aztreonam, A/S- Ampicillin- Sulbactum, CPM- Cefepime, TGC-Tigecycline, LE- Levofloxacin, AK- Amikacin, PB- Polymyxin B, CB- Carbenicillin, TOB- Tobramycin, FO-Fosfomycin, NIT- Nitrofurantoin CONCLUSION This study shows a clearer spectrum of the current CRGNB scenario in the hospital setup. MDR microorganisms are accelerating and becoming major problem in the area of infectious diseases. In order to control MBL producing microorganisms in a hospital/health care setup, strategies such as strict infection control measures, antibiotics resistance surveillance programs & restrict to clinicians, prescribe last resort drugs only where primary & secondary drugs are resistant and antibiotic cycling must be followed. Regular monitoring and documentation of carbapenem resistance should be done. Colistin could be a drug of choice in carbapenem resistant gram negative bacilli infections. It should be used when no other drug are effective. ACKNOWLEDGEMENTS I would like to express my heartfelt gratitude to Dr. Neelam Taneja, Sr. Professor Microbiology, PGI Chandigarh. It would not have been possible without your guidance and constant supervision as well as for providing necessary information regarding this project. REFERENCES 1. Gould TM. The epidemiology of antibiotic resistance. Int J Antimicrob Agent. 2008; 32(Suppl 1):S2-9. 2. Kombe GC, Darrow DM. Revisiting emerging infectious diseases: the unfinished agenda. J Community Heal. 2001;26:113-122 31 P a g e Int J Med Res Prof.2016; 2(3); 28-32. www.ijmrp.com

3. Irfan s, Zafar A, guhar D, Ahsan T, Hasan R. metallo b- lactamase producing clinical unit patients of a tertiary care hospital.indian j.med.res 2008;243-45s 4. CRE toolkit, CDC-Guidance of control of carbapenems resistant, Enterobacteriacese (CRE),2012. [Accessed 26 Jun 2012]. Available from: http://www.cdc.gov/ hai/organisms/cre/trackingcre.html 5. Datta P, Gupta V, Garg S, Chandra J. Phenotpic method for differentiation of carbapemases in Enterobacteriacese study from north India. Indian j pathol microbial 2012;55:357-360 6. Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem-A review of its use in the treatment of serious bacterial infection, Drug 2008;68:803-838 7. Queenam Am, Bush k. carbapenemases: the versatile B - lactamases clinical microbiology reviews 2007;20:440-458 8. Collee J. G., Fraser A. G., Marmion B. P., Simmons A., (Eds.), Mackie and McCartney, Practical Medical Microbiology, 1996, 14th Edition, Churchill Livingstone. 9. CLSI guideline: Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement, 2014. Available at: http://ncipd.org/control/images/ncipd_docs/clsi_m100- S24.pdf 10. EM092, Hi-Media: Meropenem with & without EDTA Ezy MIC Strips manual. Available at: http://www.himedialabs.com/intl/en/products/microbiology/antimi crobial-susceptibility-ezy-mic%e2%84%a2-strips-dual- Antibacterial/Meropenem-with-without-EDTA-EM092 11. Taneja N, Aharwal SM, Sharma M. Imipenem resistance in nonfermentors causing nosocomial urinary tract infections. Indian J Med Sci. 2003;57:294-9. 12. Gupta E, Mohanty S, Sood S. Emerging resistance to carbapenems in tertiary care hospital in north India. Indian J Med Res, 2006;124:95-98 13. Gladstone P, Rajendran P, Brahmadathan KN. Incidence of carbapenem resistant nonfermenting gram negative bacilli from patients with respiratory infections in the intensive care units. Indian J Med Microbiol 2005;23:189-91. 14. Deshpande P, Rodrigues C, Shetty A, Kapadia F, Hedge A, Soman R. New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised. J Assoc Physicians India. 2010 Mar; 58:147-9. 15. Wattal C, Goel N, Oberoi JK. Surveillance of multidrug resistant organisms in tertiary care hospital in delhi india.j assoc physicians india 2010;58:32-36. 16. Varaiya A, Kulkarni M, Bhalekar P, Dogra J. Incidence of metallo-beta-lactamase producing Pseudomonas aeruginosa in diabetes and cancer patients. Indian J. Med. Res. 2008;243-45 17. Shashikala, Kanungo R, Srinivasan S, Devi S. Emerging resistance to carbapenems in hospital acquired Pseudomonas infection: A cause for concern. Indian J Pharmacol. 2006;38:287-88 18. Nagaraj S, Chandran SP, Shamanna P, Macaden R. Car bapenem resistance among Escherichia coli and Klebsiella pneumoniaeae in a tertiary care hospital in south India. In dian J Med Microbiol 2012;30:93-95. [ Source of Support: Nil. Conflict of Interest: None Declared. Copyright: the author(s) and publisher. IJMRP is an official publication of Ibn Sina Academy of Medieval Medicine & Sciences, registered in 2001 under Indian Trusts Act, 1882. This is an open access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Cite this article as: Monika Saini, Aditya Mishra, Sweta Gupta. Prevalence of Carbapenem Resistance in Gram Negative Bacilli Isolates and Their Antimicrobial Susceptibility Pattern. Int J Med Res Prof. 2016; 2(3):28-32. 32 P a g e Int J Med Res Prof.2016; 2(3); 28-32. www.ijmrp.com